Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA

Bladder cancer is the most common type of urothelial cancer. When the disease has spread to other parts of the body (metastatic disease), the prognosis is often poor, because there are only a few effective treatment options available. At the moment, standard treatment mainly includes systemic therapies, such as chemotherapy and immunotherapy (immune checkpoint inhibitors). These treatments act on the whole body. However, the use of local treatments, such as stereotactic radiotherapy, has not been well studied in bladder cancer. Stereotactic radiotherapy is a type of radiation treatment that

Trial Details

NCT ID
NCT07413523
Phase
NA
Sponsor
Istituto Clinico Humanitas
Status
RECRUITING
Cancer Type
Bladder Cancer
Interventions
  • SBRT
Locations (sample)
  • Rozzano, Milan, Italy|45.38193,9.1559

Key Eligibility Criteria

  • Age \> 18 years
  • WHO performance status ≤ 2
  • Pathological proven urothelial carcinoma
  • Stage IV disease at imaging

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Bladder Cancer Trials on Trialify →